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ABSTRACT
Background and Objectives: In our previous study, we found that the gene transfer of a potent derivative of cartilage oligo-
meric matrix protein Angiopoietin-1 (COMP-Ang-1) substantially prevented hypertension, microvascular rarefaction, and 
target organ damage in spontaneously hypertensive rats (SHRs). The purpose of the present study was to examine the role 
of nitric oxide (NO) in the therapeutic effects observed after COMP-Ang-1 gene transfer. Materials and Methods: To exclude 
the NO-mediated effects in COMP-Ang-1 gene therapy, the SHRs were treated with an NO synthase (NOS) inhibitor, N
w-ni-
tro-L-arginine methyl ester (L-NAME) before the electrophoretic gene transfer. Results: The pretreatment with L-NAME in-
duced a severe and sustained increase in systolic blood pressure (BP) in a LacZ plasmid transferred control SHR. However, 
the electrophoretic transfer of a COMP-Ang-1 plasmid instead of LacZ plasmid in L-NAME-pretreated SHRs substantially 
blocked the development of hypertension without any significant difference in comparison with L-NAME-untreated COMP-
Ang-1 plasmid transferred groups. In addition, the COMP-Ang-1 plasmid transfer substantially attenuated microvascular rar-
efaction and arteriole remodeling in the heart and kidney, which might account for the mild histological alterations observed 
in the COMP-Ang-1 plasmid transferred group, in contrast to the severe fibrosis and necrosis seen in the LacZ plasmid con-
trols. Conclusion: These therapeutic outcomes of COMP-Ang-1 gene transfer even in NOS inhibited SHRs suggested that 
the antihypertensive effect of COMP-Ang-1 was not merely secondary to NO-mediated vasorelaxation, but it may be associ-
ated with its ability to protect the vascular endothelium probably via an NO-independent mechanism which serves to attenu-
ate microvascular rarefaction and target organ damage, and also to prevent hypertension by reducing peripheral vascular re-
sistance. (Korean Circ J 2011;41:590-595)
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Introduction
Hypertension is a cardiovascular risk factor in which sus-
tained high blood pressure (BP) causes constriction of the 
microvasculature, making it unperfused and thereby, leading 
to the dysfunction of target organs such as the heart and kid-
ney.
1)2) In particular, these hypertension-related structural and 
functional alterations of the microvasculature termed as mi-
crovascular rarefaction, also increase peripheral vascular re-
sistance, which further elevate the BP.
2)3) To break the vicious 
cycle between hypertension and microvascular rarefaction, 
many therapeutic approaches have been focused on lower-
ing BP using adrenergic receptor antagonists, calcium chan-
nel blockers and others.
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on breaking the cycle by protecting the vascular endothelium 
against a variety of stress factors in order to inhibit microvas-
cular rarefaction and the subsequent development of hyper-
tension.
5) 
With this in mind, we previously investigated the thera-
peutic effect of an endothelial survival factor, Angiopoietin-1 
(Ang-1), in prevention of hypertension and target organ da-
mage in spontaneously hypertensive rats (SHRs), a model of 
essential hypertension characterized by vascular rarefaction 
and target organ damage.
6) 
In that particular study, the electroporation-mediated tr-
ansfer of a plasmid encoding a strong and potent variant of 
Ang-1, cartilage oligomeric matrix protein (COMP)-Ang-1, 
was found to be effective in preventing hypertension and re-
ducing target organ damage in SHRs. Of note, COMP-Ang-1 
was shown to substantially increase the plasma level of nitrite, 
a metabolite of nitric oxide (NO), through the endothelial-
specific Tie2/endothelial NO synthase (eNOS) signaling pa-
thway. 
NO plays an important role in controlling BP by regulat-
ing vasodilation and it is also important for maintaining en-
dothelial homeostasis. Therefore, the increased NO synthe-
sis by COMP-Ang-1 was postulated to be a possible under-
lying mechanism for the beneficial effects of COMP-Ang-1, 
although further experiments were needed to support this 
interpretation.
The present study aimed to investigate whether or not NO 
was a key player in the overall therapeutic effects of COMP-
Ang-1 in SHRs. To address this question, SHRs were pretr-
eated with an NOS inhibitor, N
w-nitro-L-arginine methyl es-
ter (L-NAME), in order to exclude the NO-mediated effects 
of COMP-Ang-1. In NOS inhibited SHRs, BP and histopa-
thological changes in target organs were evaluated following 
COMP-Ang-1 plasmid transfer.
Materials and Methods
Animal experiments
Six-week-old male SHRs (Charles River Laboratories, Yo-
kohama, Japan) were randomized for how many electropho-
retic transfers (eight electric pulses of 200 V/cm for 50 ms at 
1 Hz using an ECM 830 electroporator; BTX Division of Ge-
netronics, San Diego, CA, USA) of plasmids encoding LacZ 
(pLacZ, the control plasmid) or COMP-Ang-1plasmid (pCO-
MP-Ang-1) (100 µg of plasmid in 100 mL of half-saline so-
lution) into the adductor muscle, as previously described.
6) For 
chronic NOS inhibition, SHRs were restricted to drinking wa-
ter containing 50 mg/L of L-NAME (Sigma, St. Louis, MO, 
USA) from one week before the gene transfer until the day 
of sacrifice.
7)8) 
For surgical procedures, rats were anesthetized with an 
intraperitoneal injection of ketamine-xylazine (50 mg/kg and 
2 mg/kg, respectively). Systolic BP was measured non-inva-
sively how frequently using the tail-cuff method (IITC Life 
Science Instruments, Woodland Hills, CA, USA) in consci-
ous rats on three different occasions. All rats were acclimat-
ed to the system one week before starting the experiment. 
The animal experiments were performed in accordance with 
the Guidelines for the Care and Use of Laboratory Animals 
published in the US National Institutes of Health (NIH pub-
lication no. 85-23, revised 1996).
Measurement of nitrite concentration 
The concentration of nitrite, a metabolite of NO, in the blo-
od was measured with an NO assay kit (R&D Systems, Min-
neapolis, MN, USA) according to the manufacturer’s instruc-
tions. As NO is rapidly metabolized mainly to nitrite or ni-
trate, the concentrations of both these anions were used as a 
quantitative measure of NO production. Briefly, nitrate was 
converted into nitrite by nitrate reductase, and then the am-
ount of nitrite was measured spectrophotometrically after 
adding Griess reagent. 
Histological and immunohistochemical analysis 
of the heart and kidney
The hearts and kidneys were fixed in 4% paraformaldehyde 
and embedded in paraffin, or frozen in cryofreezing medium. 
After staining with Masson’s Trichrome stain (MT), the his-
tological changes (e.g., fibrosis, necrosis, and vascular occlu-
sion) in the ventricular walls of the hearts and the cortices of 
the kidneys were examined. For the evaluation of capillary 
density, the heart and kidney sections were stained with mou-
se anti-rat CD31 antibody (BD Pharmingen, San Diego, CA, 
USA) and mouse anti-rat RECA-1 antibody (Abcam, Cam-
bridge, UK), respectively. After incubating sections with bio-
tinylated anti-mouse antibody (Jackson ImmunoResearch, 
West Grove, PA, USA), positive immunoreactivity was visu-
alized using ABC-peroxidase kits (ChemMate
TM DAKO En-
vision
TM Detection kit, DAKO, Copenhagen, Denmark). Con-
trols were prepared using class- and species-matched nonspe-
cific antibodies. 
Proteinuria 
Urine was collected weekly from each rat housed in a meta-
bolic cage for 24 hours. Protein levels in urine were measured 
using a Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA).
Statistical analysis
All data are presented as mean±standard error of mean 
(SEM). One-way analysis of variance was used to determine 
the significance of differences between groups; where appro-
priate, data were analyzed using post hoc Student’s t-tests for 
unpaired observations and the Bonferroni correction for 
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number of samples examined in each experiment is indicated 
by ‘n’.
Results 
Cartilage oligomeric matrix protein Angiopoietin-1 
gene transfer prevents hypertension in nitric oxide 
synthase-inhibited spontaneously hypertensive rats
To investigate the antihypertensive effect of COMP-Ang-1 
in NOS inhibited SHRs, plasmids encoding COMP-Ang-1 
or LacZ were electrophoretically transferred into L-NAME- 
pretreated SHRs, and the secretion of expressed COMP-Ang-1 
protein into the bloodstream was confirmed by as was done 
in our previous study (data not shown). In agreement with 
other reports on L-NAME-pretreated SHRs, Fig. 1A shows 
that chronic NOS inhibition induced a sustained 10-15 mm 
Hg increase in the systolic BP of pLacZ-transferred SHRs 
compared to L-NAME-pretreated pLacZ SHRs (162.3±3.7 
mm Hg in pLacZ transferred SHRs, 175.9±6.0 mm Hg in L-
NAME-pretreated pLacZ SHR).
7)8) However, the electropho-
retic transfer of pCOMP-Ang-1 substantially blocked the 
development of hypertension in NOS inhibited SHRs. Of note, 
the systolic BP of L-NAME-pretreated pCOMP-Ang-1-tr-
ansferred SHRs was not significantly different from that of 
L-NAME-untreated pCOMP-Ang-1-transferred SHRs (p= 
0.0876, n=11), which implies that COMP-Ang-1 gene trans-
fer prevented the elevation of BP mainly in an NO-indepen-
dent manner. In other words, the antihypertensive effects of 
COMP-Ang-1 might not occur through NO-mediated vaso-
relaxation. The introduction of L-NAME into the SHRs com-
pletely abolished the effect of COMP-Ang-1 on NO produc-
tion, as shown in Fig. 1B; there was no difference in the plas-
ma levels of nitrite between pLacZ- and pCOMP-Ang-1-tr-
ansferred SHRs.
Cartilage oligomeric matrix protein Angiopoietin-1 
gene transfer attenuates microvascular rarefaction 
in nitric oxide synthase inhibited spontaneously 
hypertensive rats
To analyze the effect of COMP-Ang-1 on microvascular ra-
refaction in NOS inhibited SHRs, the vasculature in target 
organs such as the heart and kidney was evaluated by immu-
nohistochemistry using endothelial specific CD31 or RECA 
antibody. As shown in Fig. 2A and B, the capillary number 
was significantly higher in the hearts from pCOMP-Ang-1-
transferred SHRs than in the hearts from pLacZ-transferred 
controls. Similar results were seen in the kidneys as well: pCO-
MP-Ang-1-transferred SHRs had more peritubular capillar-
ies and better preserved glomeruli with an intact endotheli-
um than pLacZ-transferred control (Fig. 2C). This difference 
in the microvascular rarefaction between pCOMP-Ang-1- 
and pLacZ-transferred SHRs may reflect in the histopatho-
logical differences in their target organs, as described below.
Cartilage oligomeric matrix protein Angiopoietin-1
gene transfer reduces target organ damage 
in nitric oxide synthase inhibited spontaneously 
hypertensive rats
When target organ damage was examined in NOS inhib-
ited SHRs (Fig. 3), the hearts of L-NAME pretreated pLacZ- 
transferred SHRs were found to have markedly granulated 
tissues and multifocal areas of myocardial fibrosis with obli-
terative arteriosclerosis in small arterioles. In contrast, the he-
arts of L-NAME pretreated pCOMP-Ang-1-transferred SHRs 
showed only mild alterations in the microvasculature and fe-
wer instances of myocardial fibrosis (Fig. 3A and B). In the 
kidney, L-NAME pretreated pLacZ-transferred SHRs exhib-
ited more glomerular fibrinoid necrosis and tubular intersti-
tial fibrosis than L-NAME-pretreated pCOMP-Ang-1-tr-
Fig. 1. pCOMP-Ang-1 gene transfer ameliorates hypertension in NOS inhibited SHRs. A: a significant hypotensive effect of pCOMP-Ang-1 
gene transfer was seen in L-NAME-pretreated SHRs. No significant difference (p=0.0876, n=11) was observed between L-NAME-pretreat-
ed pCOMP-Ang-1-transferred SHRs (pCOMP-Ang-1+L-NAME, 161.8±2.4 mm Hg) and L-NAME untreated pCOMP-Ang-1-transferred 
SHRs (pCOMP-Ang-1, 154.2±2.9 mm Hg). However, systolic BP of pCOMP-Ang-1+L-NAME SHRs was significantly (n=11) lower than that 
of L-NAME pretreated pLacZ-transferred SHRs (pLacZ+L-NAME, 162.3±3.7 mm Hg). The systolic BP of SHRs (in mm Hg) was measured 
using the tail-cuff method just before (white bar) and three weeks after (black bar) gene transfer. B: no significant difference (NS) was seen 
in the plasma concentration of nitrites between pLacZ+L-NAME (12.2±0.6 mM) and pCOMP-Ang-1+L-NAME SHRs (12.1±1.0 mM) (n=11).
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ansferred SHRs, which may explain the high protein content 
in their urine (Fig. 3C and D). In addition, the renal vascu-
lature in L-NAME-pretreated pLacZ SHRs showed characte-
ristics similar to those found in the heart, such as a near-com-
plete occlusion of the lumen in small arterioles rather than in 
large renal arteries. As these precapillary arterioles are recog-
nized as the critical determinants of peripheral vascular re-
sistance through their effects on hydrostatic pressure, their 
wide vascular lumen and high number in L-NAME-pretr-
eated pCOMP-Ang-1 SHRs seem to contribute to preventing 
the development of hypertension in L-NAME-pretreated SHRs. 
Discussion
In our previous study, a strong endothelial survival factor, 
COMP-Ang-1, was found to ameliorate microvascular rar-
efaction and tissue damage in the heart and kidney, and to pre-
vent the development of hypertension in a genetic hyperten-
sion animal model.
6) In particular, the high levels of NO in 
pCOMP-Ang-1-transferred SHRs have led us to postulate that 
COMP-Ang-1 lowered the systolic BP by enhancing NO-
mediated vascular relaxation, which may result in the atten-
uation of microvascular rarefaction and target organ damage. 
However, the present results obtained in L-NAME-pretreated 
SHRs showed that COMP-Ang-1 still significantly prevent-
ed the elevation of BP in SHRs when NO synthesis was inhibit-
ed. This suggested that the antihypertensive effects of COMP-
Ang-1 were not merely secondary to NO-mediated vasorelax-
ation, but they may be associated with attenuated microvas-
cular rarefaction.
Although endothelium-derived NO plays a major role in 
controlling arterial BP through endothelium-dependent va-
sorelaxation, microvascular rarefaction is another important 
factor determining BP by increasing peripheral vascular re-
sistance.
2) Since peripheral vascular resistance is mainly reg-
ulated at the distal vasculature such as small arterioles and 
capillaries where a substantial drop in intravascular pressure 
occurs, a thorough examination of the microvasculature in 
L-NAME-pretreated SHRs was performed. It was found that 
pCOMP-Ang-1-transferred SHRs displayed normal-looking 
Fig. 2. pCOMP-Ang-1 gene transfer reduces microvascular rarefaction in NOS inhibited SHRs. The microvasculature of the heart (A: red ar-
rowheads indicating the absence of blood vessels) and kidney (C: red arrowheads indicating the loss of glomerular capillaries) was visual-
ized by immunohistochemical staining with CD31 antibody for frozen sections or RECA antibody for paraffin sections. B: the capillary density 
in the heart section was quantified per myofiber (1.3±0.04 cells/myofiber in pCOMP-Ang-1+L-NAME, 0.8±0.09 cells/myofiber in pLacZ+L-
NAME, *p<0.05, n=7). Scale bar is 10 µm.
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arterioles and had a high capillary density, while pLacZ-
transferred SHRs exhibited ‘onion skin’ like arteriosclerotic 
occlusion and severe capillary rarefaction frequently. This 
difference in the microvascular structure may directly con-
tribute to preventing BP elevation in pCOMP-Ang-1-trans-
ferred SHRs. Apart from determining peripheral vascular re-
sistance, the microvasculature functions to provide sufficient 
nutrients and oxygen to the surrounding tissues in response 
to tissue demand.
3) In this regard, attenuated microvascular 
rarefaction in pCOMP-Ang-1-transferred SHRs may account 
for the observed significant preservation of the histological 
structure and function in the heart and kidney. 
Although the eNOS/NO pathway plays a crucial role in ma-
intaining endothelial homeostasis as well as in regulating 
vascular tone, several studies have reported that hyperten-
sion and arterial rarefaction in eNOS knockout mice were 
completely rescued by hyralazine hydralazine, a non-specific 
vasodilator.
9)10) These data indicated that NO plays a major 
role in hypertension by regulating systemic BP through en-
hancing vasodilation, but that this role does not include the 
maintenance of microvascular structure by protecting the 
endothelium from other hypertensive stresses. Considering 
this role of NO in hypertension, the antihypertensive effects 
induced by COMP-Ang-1 gene transfer in NOS inhibited 
SHRs would be secondary to the endothelial protective ef-
fects induced by pCOMP-Ang-1 transfer, and this should lead 
to a better preserved microvasculature.
In a variety of animal models, COMP-Ang-1 has been sh-
own to enhance endothelial survival under vascular stress. 
COMP-Ang1 protein treatment has been reported to ame-
liorate renal injury and fibrosis by protecting peritubular 
capillaries and inhibiting inflammation.
11) COMP-Ang-1 has 
been also shown to protect the capillary endothelium of the 
intestinal villi from radiation-induced apoptosis.
12) In particu-
lar, COMP-Ang1 was found to significantly activate phosph-
atidylinositol 3’ kinase/Akt pathway; one of the well-known 
signaling pathways promoting endothelial survival and in-
hibiting endothelial apoptosis. In this regard, such a role of 
COMP-Ang1 in endothelial protection seems to be associated 
with Akt signaling pathway. However, COMP-Ang-1 might 
not protect the endothelium via eNOS/NO pathway, since 
COMP-Ang-1 enhances angiogenesis and blood flow even 
in eNOS or inducible NOS knockout mice. This result indi-
cates that the activation of the eNOS/NO cascade might not 
be required for its actions on the endothelium.
13) 
Taken together, our results suggest that the antihyperten-
sive effects of pCOMP-Ang-1 gene transfer in SHRs might 
arise from the preservation of microvasculature, which in 
turn would be expected to attenuate target organ damage as 
well. Recently, microvascular abnormalities in hypertensive 
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Fig. 3. pCOMP-Ang-1 gene transfer attenuates myocardial and renal damage in NOS inhibited SHRs. Representative photomicrographs of 
the MT-stained heart (A: black arrowheads indicating the multifocal myocardial fibrosis) and kidney (C: black arrowheads indicating the tu-
bular interstitial fibrosis) with high-power images of small arterioles (right bottom insets). B: the fibrotic area shown in the MT-stained heart 
sections was quantified as a percentage relative to the total tissue area (20.7±3.0% in pCOMP-Ang-1+L-NAME, 42.2±0.08% in pLacZ+L-
NAME, *p<0.05, n=7). D: Kidney function was determined by measuring the amount of protein in the urine collected at the end of the ex-
periment (1.0±0.1 mg/mL in pCOMP-Ang-1+L-NAME, 1.6±0.03 mg/mL in pLacZ+L-NAME, *p<0.05, n=4). Scale bar is 10 µm. Wonhee Suh, et al.   595
patients have been appreciated as a cause, and not merely a 
consequence of hypertension. Indeed, several recent studies 
have reported that treatment of SHRs with a potent vasodi-
lator, hydralazine, significantly decreased the BP, but did not 
ameliorate cardiac remodeling and renal failure, suggesting 
that controlling BP itself does not fully prevent or cure hy-
pertension-related target organ damage.
14)15) In this regard, 
endothelial survival factors aimed at protecting the micro-
vasculature could therefore serve as new antihypertensive ag-
ents with therapeutic advantages in preventing hypertension-
associated target organ damage above and beyond those of 
the treatment aimed at controlling BP directly.
16-19) 
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